Cooperative-Agreement
Cooperative-Agreement funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
FY 2027 Fulbright Specialist Program: $4.600,000 Cooperative Agreement for Global One-Way Exchanges
The FY 2027 Fulbright Specialist Program funds a U.S. non-profit or educational institution to run global short-term specialist exchanges requested by U.S. embassies and partner institutions.
NSF 24-573: Focused EPSCoR Collaborations Program (FEC)
A USA-based collaborative federal program that funds interjurisdictional STEM research infrastructure upgrades through EPSCoR-eligible institutions, with a recurring annual full proposal deadline and required letter of intent.
PAR-25-051: Blueprint Neurotherapeutics Network (BPN) Small-Molecule Drug Discovery (UG3/UH3)
NIH's PAR-25-051 NOFO funds small-molecule neuroscience drug discovery teams in UG3/UH3 phases, with NIH-provided development support through the Blueprint Neurotherapeutics Network.
PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (U24)
The NHLBI PAR-27-013 funding opportunity supports Data Coordinating Center (DCC) teams that coordinate multi-site investigator-initiated clinical trials in a milestone-driven cooperative agreement, submitted alongside a companion Clinical Coordinating Center application.
RFA-MH-26-120: BRAIN Initiative Reagent Resources for Brain Cell Type-Specific Access (U24)
NIH’s BRAIN Initiative cooperative agreement funds facilities that produce and distribute brain cell type-specific access and manipulation reagents for neuroscience users.
RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)
NIH BRAIN Initiative cooperative agreement to accelerate translational development of recording and modulation devices for CNS disorders through milestone-driven UG3/UH3 funding and small clinical studies requiring FDA IDE pathways.